Amylyx Pharmaceuticals Inc
AMLX8.070USD
+0.355+4.60%
取引時間 （ET）15分遅れの株価
718.88M時価総額
損失額直近12ヶ月PER
詳細情報 Amylyx Pharmaceuticals Inc 企業名
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
企業情報
企業コードAMLX
会社名Amylyx Pharmaceuticals Inc
上場日Jan 07, 2022
最高経営責任者「CEO」Mr. Justin Klee
従業員数123
証券種類Ordinary Share
決算期末Jan 07
本社所在地43 Thorndike Street
都市CAMBRIDGE
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号02141
電話番号16176820917
ウェブサイトhttps://www.amylyx.com/
企業コードAMLX
上場日Jan 07, 2022
最高経営責任者「CEO」Mr. Justin Klee
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
194.38K
+40.46%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Mr. James M. Frates
Mr. James M. Frates
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen M. Firestone
Ms. Karen M. Firestone
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Mr. Justin Klee
Mr. Justin Klee
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
194.38K
+40.46%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
収益内訳
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
データなし
地域別USD
会社名
収益
比率
United States
87.37M
0.00%
事業別
地域別
データなし
株主
更新時刻: Fri, Jul 25
更新時刻: Fri, Jul 25
株主統計
種類
株主統計
株主統計
比率
Perceptive Advisors LLC
8.83%
TCG Crossover Management, LLC
6.67%
Adage Capital Management, L.P.
6.39%
The Vanguard Group, Inc.
5.05%
Klee (Justin B)
3.76%
Other
69.30%
株主統計
株主統計
比率
Perceptive Advisors LLC
8.83%
TCG Crossover Management, LLC
6.67%
Adage Capital Management, L.P.
6.39%
The Vanguard Group, Inc.
5.05%
Klee (Justin B)
3.76%
Other
69.30%
種類
株主統計
比率
Hedge Fund
37.33%
Investment Advisor
25.77%
Individual Investor
9.53%
Private Equity
9.22%
Investment Advisor/Hedge Fund
6.10%
Research Firm
3.54%
Venture Capital
2.72%
Pension Fund
0.22%
Sovereign Wealth Fund
0.13%
Other
5.44%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
402
86.90M
97.48%
-7.80M
2025Q1
421
95.29M
107.20%
-3.35M
2024Q4
427
70.75M
84.73%
-29.75M
2024Q3
419
63.91M
89.33%
-37.09M
2024Q2
415
63.87M
89.96%
-35.05M
2024Q1
393
69.90M
101.03%
-23.62M
2023Q4
373
76.45M
112.48%
-12.85M
2023Q3
341
74.63M
110.02%
-3.94M
2023Q2
310
76.31M
113.70%
-2.01M
2023Q1
276
73.14M
110.85%
-1.57M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Perceptive Advisors LLC
7.87M
8.83%
+1.10M
+16.24%
Mar 31, 2025
TCG Crossover Management, LLC
5.94M
6.67%
+1.30M
+27.99%
Mar 31, 2025
Adage Capital Management, L.P.
5.70M
6.39%
+5.70M
--
Mar 31, 2025
The Vanguard Group, Inc.
4.12M
4.62%
+1.42M
+52.89%
Mar 31, 2025
Klee (Justin B)
3.36M
3.76%
+235.72K
+7.56%
Apr 11, 2025
Cohen (Joshua Barry)
3.36M
3.76%
+299.42K
+9.80%
Apr 11, 2025
Millennium Management LLC
3.08M
3.46%
+2.49M
+418.62%
Mar 31, 2025
Nantahala Capital Management, LLC
2.93M
3.29%
+1.48M
+102.07%
Mar 31, 2025
Citadel Advisors LLC
2.76M
3.09%
+787.07K
+39.94%
Mar 31, 2025
Saturn V Capital Management LP
2.43M
2.72%
+1.54M
+172.92%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
iShares Neuroscience and Healthcare ETF
1.03%
Invesco Dorsey Wright SmallCap Momentum ETF
0.44%
Federated Hermes MDT Small Cap Core ETF
0.22%
iShares Micro-Cap ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Avantis US Small Cap Equity ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
詳細を見る
iShares Neuroscience and Healthcare ETF
比率1.03%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.44%
Federated Hermes MDT Small Cap Core ETF
比率0.22%
iShares Micro-Cap ETF
比率0.1%
Invesco Nasdaq Biotechnology ETF
比率0.06%
ProShares Ultra Nasdaq Biotechnology
比率0.06%
Avantis US Small Cap Equity ETF
比率0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
比率0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.04%
iShares Biotechnology ETF
比率0.04%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
